AbbVie Gets FDA Priority Review For Elagolix; Hikes Dividend - Quick Facts

AbbVie (ABBV) in cooperation with Neurocrine Biosciences, Inc. (NBIX), said that the U.S. Food and Drug Administration has granted priority review for elagolix.

from RTT - Biotech http://ift.tt/2zafrj3
via IFTTT